122 related articles for article (PubMed ID: 36682805)
21. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.
Nakabayashi M; Hayes J; Taplin ME; Lefebvre P; Lafeuille MH; Pomerantz M; Sweeney C; Duh MS; Kantoff PW
Cancer; 2013 Aug; 119(16):2990-8. PubMed ID: 23719969
[TBL] [Abstract][Full Text] [Related]
22. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
23. External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer.
Yang YJ; Lin GW; Li GX; Dai B; Ye DW; Wu JL; Xie HY; Zhu Y
Asian J Androl; 2018; 20(2):184-188. PubMed ID: 29111539
[TBL] [Abstract][Full Text] [Related]
24. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
25. Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide.
Kumano Y; Hasegawa Y; Kawahara T; Yasui M; Miyoshi Y; Matsubara N; Uemura H
Biomed Res Int; 2019; 2019():9450838. PubMed ID: 30800682
[TBL] [Abstract][Full Text] [Related]
26. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.
Hamano I; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
World J Urol; 2019 Nov; 37(11):2365-2373. PubMed ID: 30729312
[TBL] [Abstract][Full Text] [Related]
27. Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.
Choi SY; Ryu J; You D; Hong JH; Ahn H; Kim CS
Int J Urol; 2019 Jan; 26(1):62-68. PubMed ID: 30238513
[TBL] [Abstract][Full Text] [Related]
28. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H
Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769
[TBL] [Abstract][Full Text] [Related]
29. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
[TBL] [Abstract][Full Text] [Related]
30. [Risk factors for early castration-resistant prostate cancer after androgen deprivation therapy for bone-metastatic prostate cancer].
Huang FM; Li XH; Liang Y
Zhonghua Nan Ke Xue; 2018 Aug; 24(8):690-694. PubMed ID: 30173426
[TBL] [Abstract][Full Text] [Related]
31. Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
Dambal S; Howard LE; Allott EH; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
J Urol; 2020 Jan; 203(1):120-127. PubMed ID: 31430247
[TBL] [Abstract][Full Text] [Related]
32. Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study.
Zacho HD; Gade M; Mortensen JC; Bertelsen H; Boldsen SK; Barsi T; Petersen LJ
Urology; 2017 Oct; 108():135-141. PubMed ID: 28760556
[TBL] [Abstract][Full Text] [Related]
33. Survival and clinical metastases among prostate cancer patients treated with androgen deprivation therapy in Sweden.
Banefelt J; Liede A; Mesterton J; Stålhammar J; Hernandez RK; Sobocki P; Persson BE
Cancer Epidemiol; 2014 Aug; 38(4):442-7. PubMed ID: 24875326
[TBL] [Abstract][Full Text] [Related]
34. The role of adrenal derived androgens in castration resistant prostate cancer.
Barnard M; Mostaghel EA; Auchus RJ; Storbeck KH
J Steroid Biochem Mol Biol; 2020 Mar; 197():105506. PubMed ID: 31672619
[TBL] [Abstract][Full Text] [Related]
35. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
36. Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress.
Shiota M; Fujimoto N; Itsumi M; Takeuchi A; Inokuchi J; Tatsugami K; Yokomizo A; Kajioka S; Uchiumi T; Eto M
Ann Oncol; 2017 Mar; 28(3):569-575. PubMed ID: 27993795
[TBL] [Abstract][Full Text] [Related]
37. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
Sartor O; Coleman RE; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Vogelzang NJ; Bruland Ø; Kobina S; Wilhelm S; Xu L; Shan M; Kattan MW; Parker C
Ann Oncol; 2017 May; 28(5):1090-1097. PubMed ID: 28453701
[TBL] [Abstract][Full Text] [Related]
38. Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer.
Hah YS; Lee JS; Rha KH; Hong SJ; Chung BH; Koo KC
Sci Rep; 2019 Aug; 9(1):11899. PubMed ID: 31417160
[TBL] [Abstract][Full Text] [Related]
39. Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.
Shigeta K; Kosaka T; Hongo H; Yanai Y; Matsumoto K; Morita S; Mizuno R; Shinojima T; Kikuchi E; Oya M
Int J Clin Oncol; 2019 May; 24(5):546-553. PubMed ID: 30604159
[TBL] [Abstract][Full Text] [Related]
40. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]